NO991316L - 3-merkaptoacetylamino-1,5-substituerte-2-okso-azepanderivater som er anvendbare som inhibitorer av matriksmetalloproteinase - Google Patents

3-merkaptoacetylamino-1,5-substituerte-2-okso-azepanderivater som er anvendbare som inhibitorer av matriksmetalloproteinase

Info

Publication number
NO991316L
NO991316L NO991316A NO991316A NO991316L NO 991316 L NO991316 L NO 991316L NO 991316 A NO991316 A NO 991316A NO 991316 A NO991316 A NO 991316A NO 991316 L NO991316 L NO 991316L
Authority
NO
Norway
Prior art keywords
mercaptoacetylamino
oxo
inhibitors
substituted
matrix metalloproteinase
Prior art date
Application number
NO991316A
Other languages
English (en)
Norwegian (no)
Other versions
NO991316D0 (no
Inventor
Alan M Warshawsky
Gary A Flynn
Meena V Patel
Douglas W Beight
Joseph P Burkhart
Jiu-Tsair Tsay
Michael J Janusz
Jian Shen
Ramalinga M Dharanipragada
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of NO991316D0 publication Critical patent/NO991316D0/no
Publication of NO991316L publication Critical patent/NO991316L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO991316A 1996-09-19 1999-03-18 3-merkaptoacetylamino-1,5-substituerte-2-okso-azepanderivater som er anvendbare som inhibitorer av matriksmetalloproteinase NO991316L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71929196A 1996-09-19 1996-09-19
PCT/US1997/013738 WO1998012211A1 (en) 1996-09-19 1997-08-04 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase

Publications (2)

Publication Number Publication Date
NO991316D0 NO991316D0 (no) 1999-03-18
NO991316L true NO991316L (no) 1999-05-18

Family

ID=24889504

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991316A NO991316L (no) 1996-09-19 1999-03-18 3-merkaptoacetylamino-1,5-substituerte-2-okso-azepanderivater som er anvendbare som inhibitorer av matriksmetalloproteinase

Country Status (20)

Country Link
EP (1) EP0928291B1 (de)
JP (1) JP3962091B2 (de)
KR (1) KR100545460B1 (de)
CN (1) CN1150205C (de)
AR (1) AR009363A1 (de)
AT (1) ATE229034T1 (de)
AU (1) AU718055B2 (de)
BR (1) BR9713207A (de)
CA (1) CA2266759C (de)
DE (1) DE69717647T2 (de)
DK (1) DK0928291T3 (de)
ES (1) ES2184126T3 (de)
HU (1) HUP9904165A3 (de)
IL (2) IL129035A0 (de)
NO (1) NO991316L (de)
NZ (1) NZ334490A (de)
PT (1) PT928291E (de)
TW (1) TW445262B (de)
WO (1) WO1998012211A1 (de)
ZA (1) ZA978307B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1817700A (en) * 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
US6770640B1 (en) 1998-12-31 2004-08-03 Aventis Pharmaceuticals Inc. 1-Carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of MMP-12
EP1150951A1 (de) * 1998-12-31 2001-11-07 Aventis Pharmaceuticals Inc. 3-substituierte pyrrolidine und ihre verwendung als matrixmetalloproteinase-hemmer
US6486193B2 (en) 1998-12-31 2002-11-26 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
CA2360305A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Company Lactam inhibitors of fxa and method
WO2001034600A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
US6534498B1 (en) 1999-11-10 2003-03-18 Smithkline Beecham Corporation Protease inhibitors
JP2003513971A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテア−ゼ阻害剤
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
AU2001243441B2 (en) 2000-03-21 2004-11-25 Smithkline Beecham Corporation Protease inhibitors
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US7704521B2 (en) 2007-04-11 2010-04-27 Zinpro Corporation Rumen protected essential amino acids
US20080255234A1 (en) * 2007-04-11 2008-10-16 Zinpro Corporation Rumen protected lysine
CN110770340B (zh) 2017-05-31 2023-09-19 Brain生物科技股份公司 在宿主细胞中丝氨酸蛋白酶的表达的优化

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE106087T1 (de) * 1987-03-17 1994-06-15 Res Corp Technologies Inc Synthetische inhibitoren von säugetier- collagenase.
JPH07304746A (ja) * 1994-05-11 1995-11-21 Kanebo Ltd 新規ベンゾアゼピンカルボン酸誘導体
CZ288436B6 (en) * 1994-10-05 2001-06-13 Darwin Discovery Ltd Peptidyl derivatives, their therapeutic use as inhibitors of metalloproteinases and pharmaceutical preparation in which they are comprised
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids

Also Published As

Publication number Publication date
DK0928291T3 (da) 2003-03-17
HUP9904165A2 (hu) 2000-03-28
AU718055B2 (en) 2000-04-06
ES2184126T3 (es) 2003-04-01
CA2266759C (en) 2004-10-26
IL129035A (en) 2006-12-10
NZ334490A (en) 2000-08-25
KR100545460B1 (ko) 2006-01-24
DE69717647T2 (de) 2003-09-25
HUP9904165A3 (en) 2002-01-28
JP3962091B2 (ja) 2007-08-22
AU3827897A (en) 1998-04-14
CN1234039A (zh) 1999-11-03
BR9713207A (pt) 2000-04-04
PT928291E (pt) 2003-03-31
KR20000036246A (ko) 2000-06-26
CA2266759A1 (en) 1998-03-26
EP0928291B1 (de) 2002-12-04
WO1998012211A1 (en) 1998-03-26
DE69717647D1 (de) 2003-01-16
ATE229034T1 (de) 2002-12-15
TW445262B (en) 2001-07-11
AR009363A1 (es) 2000-04-12
HK1020741A1 (en) 2000-05-19
IL129035A0 (en) 2000-02-17
ZA978307B (en) 1998-03-19
JP2001501926A (ja) 2001-02-13
NO991316D0 (no) 1999-03-18
EP0928291A1 (de) 1999-07-14
CN1150205C (zh) 2004-05-19

Similar Documents

Publication Publication Date Title
DK0946512T3 (da) 6-Phenylpyridyl-2-aminderivater, der er nyttige som NOS-inhibitorer
NO984917D0 (no) Ureaderivater som inhibitorer av IMPDH-enzym
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
DK1001934T3 (da) Indolforbindelser som COX-2-inhibitorer
NO980467D0 (no) 4-mercaptopyrrolidin-derivater som farnesyl-transerase-inhibitorer
NO986090D0 (no) Fenylalaninderivater som integrininhibitorer
NO992821D0 (no) Ketobenzamider som calpain-inhibitorer
NO982185D0 (no) Nye makrosykliske forbindelser som metalloproteaseinhibitorer
NO991316D0 (no) 3-mercaptoacetylamino-1,5-substituerte-2-okso-azepanderivater som er anvendbare som inhibitorer av matriksmetalloproteinase
DK1097127T3 (da) Diacylhydrazinderivater som integrininhibitorer
DK0891362T3 (da) Pyrrolopyrrolon derivater som inhibitorer for neutrofil elastase
NO20010331L (no) Ftalazinderivater som fosfodiesterase 4-inhibitorer
FI973198L (fi) Silloitetut indolit matriisimetalloproteaasi-inhibiittoreina
NO991994L (no) Substituerte 4-bifenyl-4-hydroksysm°rsyrederivater som matriksmetalloproteaseinhibitorer
NO20003828D0 (no) 2,3,4,5-Tetrahydro-1H-[1,4]-benzodiazepin-3-hydroksamsyrer som matriks-metalloproteinaseinhibitorer
NO20010568D0 (no) Substituerte imidazo[1,2a]aziner som selektive inhibitorer for cox-2
DK0747346T3 (da) N-acyl-2-arylcyclopropylmethylaminderivater som melatonerge midler
NO20001200D0 (no) Pyrrolopyrrolonderivater som inhibitorer av neurofil elastase
ATE205822T1 (de) Substituierte 4-arylbutyrsäurederivate als matrix metalloprotease inhibitoren
NO20000094L (no) 6-Azaurcilderivater som IL-5 inhibitorer
FI960730A7 (fi) Indolijohdannaiset 5alfa-reduktaasi-1-inhibiittoreina
DK0944601T3 (da) Heterocykliske quanidinylaminoforbindelser som alfa-2-adrenoceptoragonister
NO20011654D0 (no) Benzamidderivater som trombininhibitorer
DK1115708T3 (da) Aminoalkyl-3,4-dihydriquinolinderivater som NO-synthaseinhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application